UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit

Rosen Law Firm announced a securities fraud class action against Unicycive Therapeutics on behalf of purchasers of UNCY securities between December 29, 2025 and June 29, 2026, with a lead plaintiff deadline of November 2, 2026. The complaint alleges Unicycive never inspected or audited its third-party manufacturing vendor's facility, leaving investors unaware of FDA deficiencies and of a material risk that approval of oxylanthanum carbonate (OLC) would be delayed.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.